NCT05036226 2026-03-30
COAST
Medical University of South Carolina
Phase 1/2 Recruiting
Clinical Trials
8 trialsNCT00652574 2022-10-31
Dasatinib in Resectable Malignant Pleural Mesothelioma
M.D. Anderson Cancer Center
Phase 1 Completed
NCT02638428 2020-03-19
Genomics-Based Target Therapy for Children With Relapsed or Refractory Malignancy
Samsung Medical Center
Phase 2 Unknown
NCT00662636 2017-03-23
Dasatinib and Lapatinib Ditolsylate in Treating Patients With Advanced Solid Tumors That Cannot Be Removed By Surgery
Mayo Clinic
Phase 1 Completed
NCT00509041 2016-08-11
Dasatinib in Treating Patients With Previously Treated Malignant Mesothelioma
Alliance for Clinical Trials in Oncology
Phase 2 Completed
NCT00388427 2015-05-28
Safety Study Of Cetuximab Plus Dasatinib (BMS-354825) in Treating Advanced Solid Malignancies
University of Pittsburgh
Phase 1 Completed
NCT00429234 2013-04-04
Gemcitabine and Dasatinib in Advanced Solid Tumors
M.D. Anderson Cancer Center
Phase 1 Completed
NCT00495872 2012-10-18
Valproic Acid-Based 2-Agent Oral Regimens for Patients With Advanced Solid Tumor
M.D. Anderson Cancer Center
Phase 1 Completed